A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

This study is ongoing, but not recruiting participants.

First Received: October 28, 2002 Last Updated: June 23, 2005 History of Changes

Sponsor:	Trimeris
Information provided by:	Trimeris
ClinicalTrials.gov Identifier:	NCT00048217

Purpose

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Condition	Intervention	Phase
HIV Infections	Drug: T-1249	Phase I Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Open Label Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: AIDS

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Completion T1249-102;
Currently failing a T-20 containing regimen

Exclusion Criteria:

Non-completion of T1249-102.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217

Locations

United States, North Carolina
Trimeris
Durham, North Carolina, United States, 27707

Sponsors and Collaborators

Trimeris

More Information

No publications provided

Study ID Numbers:	T1249-105
Study First Received:	October 28, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00048217 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Trimeris:

Treatment Experienced

Additional relevant MeSH terms:

Virus Diseases
Sexually Transmitted Diseases, Viral
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
HIV Infections

Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
Immunologic Deficiency Syndromes

ClinicalTrials.gov processed this record on March 18, 2010